# RANKL Inhibition to Combat Sarcopenia in Hip Fracture Patients

> **NCT07056478** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Prince of Wales Hospital, Shatin, Hong Kong** · enrollment: 130 (estimated)

## Conditions studied

- Sarcopenia in Elderly

## Interventions

- **DRUG:** Denosumab (Prolia)
- **DRUG:** Zoledronic acide (Aclasta)

## Key facts

- **NCT ID:** NCT07056478
- **Lead sponsor:** Prince of Wales Hospital, Shatin, Hong Kong
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01-01
- **Primary completion:** 2028-01-01
- **Final completion:** 2030-01-01
- **Target enrollment:** 130 (ESTIMATED)
- **Last updated:** 2025-07-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07056478

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07056478, "RANKL Inhibition to Combat Sarcopenia in Hip Fracture Patients". Retrieved via AI Analytics 2026-09-24 from https://api.ai-analytics.org/clinical/NCT07056478. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*